PathAI Announces Collaboration with Akoya Biosciences to Offer a Spatial Biology and AI-Powered Analysis Solution
Collaboration brings together PathAI’s market-leading AI-powered technology and Akoya’s spatial phenotyping capabilities to offer a complete spatial biology solution for biopharma partners
Boston, Massachusetts – PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced a strategic collaboration to offer biopharmaceutical organizations AI-powered data analysis services for spatial multiplexed data sets. The partnership combines PathAI’s AI-based platforms with Akoya’s Phenoptics™ spatial phenotyping platform to provide a complete spatial biology solution for biomarker-guided drug development.
The collaboration between PathAI and Akoya offers the biopharmaceutical industry the most advanced and comprehensive capabilities to leverage spatial phenotyping biomarkers to advance their clinical programs.” said Brian McKelligon, CEO of Akoya. “The combination of Akoya’s spatial biology platforms and PathAI’s AI-powered technology has the potential to transform biomarker efforts in translational research, clinical development — and ultimately cancer care.”
As part of the partnership, spatial data from Akoya’s Phenoptics platform can be integrated with PathAI’s AI-based platforms to discover and validate novel spatial signatures to predict patient outcomes, molecular phenotypes, or other biologically relevant insights. The advanced insights from these analyses will accelerate the development of multiplex spatial signatures, while also supporting the translation of these biomarkers into predictive assays and clinical diagnostic tools.
“It has been very challenging to analyze high dimensional data sets using traditional tools. By applying PathAI’s advanced artificial intelligence methods to these data sets, we can greatly increase our ability to derive biologically and clinically meaningful insights,” said Dr. Andy Beck, CEO of PathAI. “Our collaboration with Akoya will provide our biopharmaceutical partners a differentiated solution for analyzing multiplex spatial data and, eventually, provide new diagnostic tools to improve patient outcomes.”
Dr. Michael Montalto, Chief Scientific Officer of PathAI, will discuss the role of AI in spatial biomarker development at Akoya’s Spatial Day Event on December 15, 2021. Register here.
About PathAI
PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine. To learn more, visit pathai.com.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. For more information, please visit www.akoyabio.com/
SOURCE: PathAI
